Navigation Links
Antibody Engineering Company F-Star Buys Back Royalty Obligations

TVM Capital Joins Investor Syndicate

VIENNA, Austria, March 28 /PRNewswire/ -- f-star, an antibody engineering company developing novel antibodies and antibody fragments based on its unique Modular Antibody Technology, announced today that it has acquired future royalty obligations to New Century Pharmaceuticals (NCP) via a one-off payment.

Modular Antibody Technology was originally developed by Prof. Florian Rueker, one of f-star's founders, in collaboration with NCP, a U.S. biopharmaceutical company. After f-star's foundation, NCP became one of the Company's common shareholders and had rights to future royalty payments. In the course of the transaction, f-star has now bought back these royalty obligations and TVM Capital, a transatlantic venture capital firm based in Munich and Boston, acquired NCP's minority stake in f-star.

"We are very pleased that our technology is now essentially free of royalty obligations," Gottfried Himmler, CEO of f-star, commented on the transaction. "And we are delighted to have TVM Capital, one of the leading life science investors in Europe, joining f-star's strong international investor syndicate."

"It is an honor to become an investor in one of the leading next-generation antibody companies and to join this distinguished syndicate," Axel Polack, General Partner TVM Capital, commented.

About f-star

f-star is an antibody engineering company based in Vienna, Austria. The Company develops improved therapeutic antibodies and antibody fragments based on its Modular Antibody Technology, which allows the introduction of additional binding sites into antibodies and antibody fragments by engineering the non-CDR loops of constant or variable domains. Using Modular Antibody Technology, antibody fragments with antibody functionality and long half-life but much smaller size (Fcab(TM)) or full antibodies with additional functionality (mAb squared) can be created.

f-star was founded by a team of experienced antibody engineering and biotech executives in 2006. Seed-financed by Austrian government agencies and Atlas Venture, the Company recently closed a Series A financing round with Aescap Venture, Atlas Venture and Novo A/S and has raised EUR 13.0m in total so far. In its advisory board, the Company is supported by pioneers in the field of monoclonal antibodies. f-star has 18 employees at its headquarters in Vienna, Austria and recently opened a second research site in Cambridge, UK.

For more information, visit

About the TVM Capital Life Science Practice

The TVM Capital Life Science Practice is, with EUR 900m (USD1.3bn) under management, one of the largest investors in venture and growth deals in biotechnology and pharmaceuticals in Europe, with a strong presence in the U.S. and a growing presence in Asia. The Life Science team builds on the expertise, experience, international approach and demonstrated success in more than 100 previous investments and more than 30 IPOs from its biotechnology and pharmaceutical portfolio of companies.
For more information, visit

Company contact:

Dr. Eugen Stermetz, CFO

f-star Biotechnologische Forschungs- und Entwicklungs-GmbH


Gastgebgasse 5-13

1230 Vienna, Austria

Media contact:

Frank Butschbacher

Investor Relations & Communications


SOURCE f-star Biotechnologische Forschungs- und Entwicklungs-GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility
2. Antibody Engineering Company f-Star Opens Second Research Site in Cambridge, UK
3. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
4. Purchase Agreement for Antibody Manufacturing Facility Receives Antitrust Clearance
5. ESBATechs Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops
6. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
7. Vaccinex Antibody Licensed to GlaxoSmithKline
8. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
9. Human Genome Sciences and Xencor Announce Antibody Collaboration
10. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
11. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... -- Clintrax Global, Inc., a worldwide provider of clinical research services headquartered ... the company has set a new quarterly earnings record in Q3 ... posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , with ...
(Date:11/24/2015)... 2015 --> ... released by Transparency Market Research, the global non-invasive prenatal ... of 17.5% during the period between 2014 and 2022. ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... market to reach a valuation of US$2.38 bn by ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015 ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... 2015 Daon, a global leader in mobile ... a new version of its IdentityX Platform , ... America have already installed IdentityX v4.0 and ... FIDO UAF certified server component as an ... FIDO features. These customers include some of the largest ...
Breaking Biology News(10 mins):